4//SEC Filing
Sucampo Pharmaceuticals, Inc. 4
Accession 0001209191-14-048686
CIK 0001365216operating
Filed
Jul 22, 8:00 PM ET
Accepted
Jul 23, 6:30 PM ET
Size
11.1 KB
Accession
0001209191-14-048686
Insider Transaction Report
Form 4
Ueno Ryuji
DirectorCEO, Chief Scientific Officer10% Owner
Transactions
- Sale
Class A Common Stock
2014-07-22$6.25/sh−2,500$15,635→ 22,803,202 total(indirect: By LLC) - Sale
Class A Common Stock
2014-07-21$6.25/sh−100$625→ 22,805,702 total(indirect: By LLC) - Sale
Class A Common Stock
2014-07-23$6.32/sh−3,245$20,507→ 22,799,957 total(indirect: By LLC)
Holdings
- 60,357(indirect: By Spouse)
Class A Common Stock
- 353,530
Class A Common Stock
Footnotes (5)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by S&R Technology Holdings, LLC on September 11, 2013.
- [F2]S&R Technology Holdings, LLC is wholly owned by Dr. Ueno and his wife. Dr. Ueno disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.25 to $6.27, inclusive. The reporting person undertakes to provide to Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.35, inclusive. The reporting person undertakes to provide to Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]Dr. Ueno disclaims beneficial ownership of the reported securities.
Documents
Issuer
Sucampo Pharmaceuticals, Inc.
CIK 0001365216
Entity typeoperating
Related Parties
1- filerCIK 0001365216
Filing Metadata
- Form type
- 4
- Filed
- Jul 22, 8:00 PM ET
- Accepted
- Jul 23, 6:30 PM ET
- Size
- 11.1 KB